Carisma Therapeutics (NASDAQ:CARM) Announces Earnings Results, Meets Expectations

Carisma Therapeutics (NASDAQ:CARM) issued its quarterly earnings results on Thursday. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31), reports. The company had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 350.08% and a negative return on equity of 344.89%.

Carisma Therapeutics Price Performance

Shares of CARM stock opened at $1.01 on Friday. The firm’s 50-day moving average is $0.99 and its two-hundred day moving average is $1.15. The company has a market capitalization of $41.96 million, a PE ratio of -0.57 and a beta of 1.49. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.25 and a quick ratio of 3.25. Carisma Therapeutics has a 12 month low of $0.80 and a 12 month high of $3.16.

Analyst Upgrades and Downgrades

Separately, EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th.

Institutional Investors Weigh In On Carisma Therapeutics

A hedge fund recently bought a new stake in Carisma Therapeutics stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 26,006 shares of the company’s stock, valued at approximately $40,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.06% of Carisma Therapeutics at the end of the most recent quarter. 44.27% of the stock is currently owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.